Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 304Carcinoma, Non-Small-Cell Lung 182Ovarian Neoplasms 154Lung Neoplasms 92Esophageal Neoplasms 75Triple Negative Breast Neoplasms 71Stomach Neoplasms 71Fallopian Tube Neoplasms 68Squamous Cell Carcinoma of Head and Neck 51Esophageal Squamous Cell Carcinoma 50Neoplasm Metastasis 48Neoplasms 45Endometrial Neoplasms 42Head and Neck Neoplasms 41Carcinoma, Ovarian Epithelial 41Uterine Cervical Neoplasms 37Recurrence 26Carcinoma, Squamous Cell 23Adenocarcinoma Of Esophagus 22Urinary Bladder Neoplasms 19Melanoma 19Inflammatory Breast Neoplasms 19Prostatic Neoplasms 18Adenocarcinoma of Lung 17Carcinoma 15Breast Neoplasms, Male 15Unspecified Adult Solid Tumor, Protocol Specific 14Testicular Neoplasms 13Small Cell Lung Carcinoma 12Peritoneal Neoplasms 12

Interventions

toripalimab 3Injections 2Surveys and Questionnaires 1Pemetrexed 1Paclitaxel 1Etoposide 1Docetaxel 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Advanced Lung Cancer × Paclitaxel × Clear all
NCT05664971 2025-12-02

JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

Shanghai Junshi Bioscience Co., Ltd.

Phase 1/2 Completed
119 enrolled
Thoracic

Advanced Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡